RIEMSER Pharma

What RIEMSER Pharma does

RIEMSER Pharma GmbH is identified in the firmographic data as a specialty pharmaceutical company headquartered in Greifswald, Germany, founded in 1990 with 11-50 employees. The aggregated source material, however, is dominated by a separate but possibly related entity — an international specialty pharmaceutical company headquartered in Spain, founded approximately 1929, with 744 million euros in FY2024 net sales (5% year-over-year growth) and subsidiaries across Europe, Asia, and America. The entity's core products include specialty pharmaceuticals for rare diseases with high unmet medical need, specifically Caprelsa (Vandetanib) for medullary thyroid carcinoma and a licensed treatment for severe primary IGF-1 deficiency. Beyond proprietary products, the company offers contract development and manufacturing services (CDMO) for small-molecule active pharmaceutical ingredients from preclinical through commercial scale, and operates B2B partnering arrangements for licensing and distribution.

The business model combines direct pharmaceutical product sales (specialty/rare disease) with B2B CDMO services and licensing partnerships. Geographic distribution flows through traditional pharmaceutical channels including wholesalers, pharmacies, and direct hospital sales, anchored by wholly-owned regional subsidiaries in Europe, Asia, and America. Customer-facing engagement is structured around patient, healthcare professional, and business partner segments, with marketing executed through corporate web, LinkedIn, Instagram, and a dedicated media/news center. The acquisition history includes Intrapharm Laboratories (2015), Keocyt (2014), Riemser Speciality Production (2008), and most recently Regis Technologies (2025) and Caprelsa (2025), supplemented by a 2025 licensing agreement for IGF-1 deficiency treatment — collectively indicating an M&A-driven international expansion strategy focused on rare-disease therapeutics and CDMO scale. Historical equity backing includes TVM Capital (2008) and Nord Holding (2005).

Note: The source data exhibits a significant identity conflict between the German RIEMSER Pharma entity (Greifswald, founded 1990, 11-50 employees) and the much larger Spanish-domiciled entity described in the majority of the structured content. The analytical content above reflects primarily the dominant data narrative; the RIEMSER-specific personnel (Beate Küter, COO Germany; Magdalena Poznanski, BD manager) and earlier acquisitions point to a distinct German operation whose full profile is not disclosed in the available material.

Name

RIEMSER Pharma

Legal name

ESTEVE

Website

https://riemser.de

Company type

Private

Founded year

1929

Operating status

Operating

Headcount range

11–50 employees

Short description

RIEMSER Pharma is a specialty pharmaceutical company operating in rare diseases and CDMO services; the dominant data set describes a Spain-based international pharma with rare-disease products and contract manufacturing across Europe, Asia, and America.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Specialty pharmaceuticals
• Contract manufacturing
• Rare disease therapies
• Pharmaceutical products
• B2B partnering

Headquarters

HQ city

Greifswald

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Distribution channels3 records

Marketing channels4 records

Core offering

RIEMSER Pharma GmbH (formerly RIEMSER Arzneimittel AG) is an international specialty pharmaceutical company headquartered in Greifswald, Germany, focused on developing, marketing, and distributing specialty pharmaceutical products. The company also operates contract manufacturing (Auftragsfertigung) services and B2B partnering arrangements, and has grown through acquisitions of specialty pharma assets such as Intrapharm Laboratories, Keocyt, and Riemser Speciality Production.

Product overview

ESTEVE is an international pharmaceutical company offering a portfolio of pharmaceutical products across therapy areas, contract manufacturing services (Auftragsfertigung), and B2B partnering solutions. The company operates across multiple regions including Benelux, France, Germany, Italy, Portugal, Spain, and the UK, with subsidiaries in Asia and America. Core offerings include specialty pharmaceutical products like Caprelsa® (Vandetanib) for medullary thyroid carcinoma, an innovation pipeline, and contract development and manufacturing services for small-molecule pharmaceutical active ingredients.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty pharmaceutical product portfolio

Quantifiable outcome

• 5% net sales growth

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Regis TechnologiescoreStrategic or Co-development Partner · 31 July 2025Esteve acquired Regis Technologies to expand its presence and offerings in the United States. The acquisition enables Esteve to extend its contract development and manufacturing services for small molecule pharmaceutical active ingredients from preclinical through commercial manufacturing in the US market.
• Licensing Partner (IGF-1 Deficiency Treatment)coreOEM/ Whitelabel/ Licensing Partner · 1 April 2025Esteve signed a licensing agreement for a pharmaceutical product to treat severe primary deficiency of insulin-like growth factor-1 (primary IGF-1 deficiency). This agreement represents Esteve's strategic focus on highly specialized therapies for conditions with high unmet medical need.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dermapharm Holding: German specialty pharmaceutical company focused on niche therapeutic areas including dermatology, allergies, and pain. Comparable as a German specialty pharma player with similar focused market approach and European distribution footprint.
• Faes Farma: Spanish specialty pharmaceutical company focused on prescription and OTC products across multiple therapeutic areas. Comparable as a Southern European specialty pharma with similar niche market approach and Iberian heritage similar to Estee.
• Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty conditions. Comparable as a Southern European specialty pharma player with similar market positioning to Estee/RIEMSER and similar portfolio-based approach.
• Orion Corporation: Finnish specialty pharmaceutical company with focus on neurology, critical care, and specialty therapeutics. Comparable as a European specialty pharma player with similar market positioning and diversified specialty portfolio approach.
• Recordati: Italian-headquartered European specialty pharmaceutical company with focus on rare diseases and specialty therapeutics. Comparable as a European specialty pharma player with similar positioning in niche therapeutic areas and international growth strategy.
• Merz Pharma: German specialty pharmaceutical company focused on aesthetics, neurology, and consumer care. Comparable as a German-headquartered specialty pharma player with private ownership structure and international distribution similar to RIEMSER's positioning.
• Neuraxpharm: European specialty pharmaceutical company focused on central nervous system (CNS) disorders. Comparable as a privately-held European specialty pharma player with similar focus on niche therapeutic areas and PE-backed history.
• Stada Arzneimittel: German specialty and generics pharmaceutical company headquartered in Bad Vilbel. Directly comparable as a German specialty pharma player with similar geographic focus on European markets and a portfolio-based business model targeting niche therapeutic areas.

Broad incumbents

• Hikma Pharmaceuticals: UK-headquartered specialty and generic pharmaceutical company with global presence across MENA, Europe, and North America. Comparable as a larger specialty pharma player with similar European base and broad international distribution.
• Ipsen: French specialty pharmaceutical company focused on oncology, neuroscience, and rare diseases. Comparable as a larger incumbent specialty pharma player with similar therapeutic focus areas and European base, though with significantly greater scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/esteve

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RIEMSER Pharma